← Back to Search

Small Molecule Inhibitor

Bemcentinib for Pancreatic Cancer

Phase 1 & 2
Waitlist Available
Led By Muhammad S Beg, MD
Research Sponsored by University of Texas Southwestern Medical Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up every 4 months from time of first dose of study drug until completion of treatment for approximately 42 months.
Awards & highlights

Study Summary

This study is evaluating whether a drug called bemcentinib may help improve outcomes for individuals with pancreatic cancer.

Eligible Conditions
  • Pancreatic Cancer

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~every 4 months from time of first dose of study drug until completion of treatment for approximately 42 months.
This trial's timeline: 3 weeks for screening, Varies for treatment, and every 4 months from time of first dose of study drug until completion of treatment for approximately 42 months. for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Overall Response Rate (ORR)
Secondary outcome measures
Clinical Benefit Rate
Complete Response Rate (CR)
Number of Participants With an Adverse Event of Grade 3 or Higher

Trial Design

2Treatment groups
Experimental Treatment
Group I: Phase 2Experimental Treatment3 Interventions
bemcentinib 200 mg oral daily every 28 days. Nab-paclitaxel 125 mg/m^2 Day 1 /8 /15 every 28 days. Gemcitabine 1000 mg/m^2 Day 1 /8 /15 every 28 days.
Group II: Phase 1bExperimental Treatment4 Interventions
bemcentinib 200 mg oral daily every 21 days. Nab-paclitaxel 100 mg/m^2 Day 1 /8 every 21 days. Gemcitabine 800 mg/m^2 Day 1 /8 every 21 days. Cisplatin 25 mg/m^2 Day 1 /8 every 21 days.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Bemcentinib
2018
Completed Phase 2
~160
Nab-paclitaxel
2014
Completed Phase 3
~2030
Gemcitabine
2017
Completed Phase 3
~2070
Cisplatin
2013
Completed Phase 3
~1940

Find a Location

Who is running the clinical trial?

Triligent InternationalIndustry Sponsor
8 Previous Clinical Trials
496 Total Patients Enrolled
Translational Genomics Research InstituteOTHER
35 Previous Clinical Trials
106,985 Total Patients Enrolled
BerGenBio ASAIndustry Sponsor
13 Previous Clinical Trials
853 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Who else is applying?

What state do they live in?
Texas
California
How old are they?
18 - 65
65+
What site did they apply to?
University of Texas Southwestern Medical Center
What portion of applicants met pre-screening criteria?
Met criteria
Did not meet criteria
Recent research and studies
clinicaltrials.govStudy
Clinical Trial of Chemotherapy and Bemcentinib for Metastatic Pancreatic Cancer
Syed Kazmi 2019. "Clinical Trial of Chemotherapy and Bemcentinib for Metastatic Pancreatic Cancer". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03649321.
~7 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top